Market capitalization | $236.88m |
Enterprise Value | $45.46m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.28 |
P/S ratio (TTM) P/S ratio | 1.47 |
P/B ratio (TTM) P/B ratio | 2.14 |
Revenue growth (TTM) Revenue growth | 230.90% |
Revenue (TTM) Revenue | $160.96m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
11 Analysts have issued a Sutro Biopharma, Inc. forecast:
11 Analysts have issued a Sutro Biopharma, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 161 161 |
231%
231%
|
|
Gross Profit | 154 154 |
284%
284%
|
|
EBITDA | -123 -123 |
29%
29%
|
EBIT (Operating Income) EBIT | -130 -130 |
28%
28%
|
Net Profit | -124 -124 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sutro Biopharma Inc. engages in the drug discovery, development, and manufacturing of pharmaceutical products. It focuses on next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | William Newell |
Employees | 302 |
Founded | 2003 |
Website | www.sutrobio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.